Systematic Review with Meta-Analysis: Efficacy and Safety of Lusutrombopag for Severe Thrombocytopenia in Patients with Chronic Liver Disease Undergoing Invasive Procedures.

Adv Ther · 2022 · PMC9402754 · PMID 35836089

Europe PMC DOI

hedged sentence

0.1000

closest p · 2.0× alpha

0.1000

boldest claim

The sentences

did not reach statistical significancep > 0.1so close (0.05 < p ≤ 0.1)

Bleeding risk with lusutrombopag 3 mg treatment did not reach statistical significance compared to placebo treatment in either subgroup (GI-related procedures, p > 0.1; liver-related procedures, p = 0.071), although a trend toward lower risk after lusutrombopag treatment was observed (Fig. 4 C).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.